{"entity":{"id":"siltuximab","kind":"drug","name":"Siltuximab","aka":[],"tldr":"Siltuximab (Sylvant) is an antibody that neutralises the inflammatory messenger interleukin-6. It is the only approved treatment for multicentric Castleman disease, a rare lymph node disorder, in people without HIV or HHV-8 infection.","summary":"Siltuximab was approved by the FDA in April 2014 and by the EU in the same year for multicentric Castleman disease in HIV-negative and HHV-8-negative patients, on a randomised placebo-controlled phase 2 trial of 79 patients in which durable tumour and symptomatic responses occurred only in the siltuximab arm. Castleman disease is a lymphoproliferative disorder rather than a cancer, but it is managed by haematologist-oncologists and the NCI lists siltuximab among cancer drugs. Infusion is every three weeks indefinitely in responders. Because IL-6 blockade suppresses C-reactive protein and fever, infections may be masked; hypertriglyceridaemia and neutropenia occur. Tocilizumab, which blocks the IL-6 receptor, is used in the same disease off label.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Siltuximab","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=siltuximab"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/siltuximab"},{"label":"EPAR","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant"}],"tags":["nci-list"],"related":["tocilizumab"],"cancers":[],"sections":[],"technologies":["monoclonal-antibody"],"targets":["il6"],"drugs":[],"companies":["recordati","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07570173","nct06679829","nct03315026"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Multicentric Castleman disease is a lymphoproliferative disorder with no cancer record."],"brand":"Sylvant","modality":"Monoclonal antibody (anti-IL-6, chimeric IgG1)","mechanism":"Binds interleukin-6 directly and prevents it engaging soluble and membrane-bound IL-6 receptors, cutting the cytokine drive behind Castleman disease.","approvals":[{"region":"US","year":2014,"indication":"Multicentric Castleman disease in HIV-negative and HHV-8-negative patients"},{"region":"EU","year":2014,"indication":"Multicentric Castleman disease in HIV-negative and HHV-8-negative adults"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/siltuximab/","neighbours":{"drug":[{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"recordati","kind":"company","name":"Recordati","route":"/companies/recordati/"}],"trial":[{"id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/"},{"id":"nct06679829","kind":"trial","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","route":"/trials/nct06679829/"},{"id":"nct03315026","kind":"trial","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","route":"/trials/nct03315026/"}]}}